Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 1, 2001AJP Heart and Circulatory Physiology

Effect of ascorbic acid treatment on conduit vessel endothelial dysfunction in patients with hypertension

View Full Paper
Ask AI
Bookmark
Share

Key result

Acute (2 g) or chronic (500 mg/day for 1 month) oral ascorbic acid treatment had no effect on brachial artery endothelium-dependent, flow-mediated dilation in patients with hypertension.

Why the study?

Does acute and chronic ascorbic acid treatment improve brachial artery flow-mediated dilation in patients with hypertension?

Population

39 patients with hypertension

Comparison

Ascorbic acid acute and chronic vs Placebo

Design

RCT, randomized, double-blind, placebo-controlled

Follow-up

1 month

Authors

SDStephen J. DuffyInterventional CardiologyNGNoyan GokceCardiac ImagingMHMonika HolbrookBoston University

Discussion

Loading...

Member takes

Implication

Does not support ascorbic acid for endothelial dysfunction in hypertension; confirms null effect on FMD despite BP lowering.

Key Points

  • This study aims to determine the effect of ascorbic acid treatment on endothelial function in hypertensive patients.
  • Randomized, double-blind, placebo-controlled study with 39 hypertensive patients
  • Administered acute (2 g) and chronic (500 mg/day for 1 month) ascorbic acid
  • Measured brachial artery flow-mediated dilation and plasma ascorbic acid levels
  • Flow-mediated dilation was impaired in hypertensive patients compared to controls (8.9% vs. 11.2%, P < 0.04)
  • Plasma ascorbic acid levels significantly increased after acute and chronic treatment (P < 0.001)
  • Ascorbic acid treatment did not improve endothelial function as measured by flow-mediated dilation

Study Design

Type

RCT (n=121)

Blinding

Double-blind

Randomization

randomized

Structured PICO

Does acute and chronic ascorbic acid treatment improve brachial artery flow-mediated dilation in patients with hypertension?

P
Population
39 patients with hypertension (compared with 82 age- and gender-matched normotensive controls for baseline assessment)
I
Intervention
Ascorbic acid acute (2 g oral) and chronic (500 mg/day oral for 1 month)
C
Comparator
Placebo
O
Outcome
Brachial artery endothelium-dependent, flow-mediated dilationsurrogate

Acute and chronic oral ascorbic acid treatment does not reverse conduit vessel endothelial dysfunction in patients with hypertension, despite increasing plasma levels and lowering blood pressure.

Cite This Study

Duffy et al. (2001) conducted an RCT in Hypertension (n=121). Ascorbic acid vs. Placebo was evaluated on Brachial artery flow-mediated dilation. Acute (2 g) or chronic (500 mg/day for 1 month) oral ascorbic acid treatment had no effect on brachial artery endothelium-dependent, flow-mediated dilation in patients with hypertension.

synapsesocial.com/papers/6a10eea55e6663f9d264b034https://doi.org/10.1152/ajpheart.2001.280.2.h528

Topics

Hypertension management
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ascorbic Acid Reverses Endothelial Vasomotor Dysfunction in Patients With Coronary Artery Disease1996 · 587 citations
  2. 2Long-Term Ascorbic Acid Administration Reverses Endothelial Vasomotor Dysfunction in Patients With Coronary Artery Disease1999 · 390 citations
  3. 3Pharmacological Concentrations of Ascorbic Acid Are Required for the Beneficial Effect on Endothelial Vasomotor Function in Hypertension2000 · 156 citations
  4. 4Effects of Ascorbic Acid on Ambulatory Blood Pressure in Elderly Patients with Refractory Hypertension2011 · 41 citations
  5. 5Effect of acute and chronic ascorbic acid on flow‐mediated dilatation with sedentary and physically active human ageing2004 · 341 citations